Grace Owusu Aboagye

Grace Owusu Aboagye

Auto-generated profile, based on publicly available information

Grace Owusu Aboagye

Korle Bu Teaching Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2020 in Case Reports in Psychiatry
Verified
Journal Article
Open access
PDF file
MOMercy N. A. Opare-Addo
Mercy N. A. Opare-Addo
JMJosephine Mensah
Josephine Mensah
GAGrace Owusu Aboagye
Grace Owusu Aboagye
Schizophrenia is a chronic and severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behaviour. This report presents the role of clinical pharmacists in the management of a patient diagnosed with schizophrenia with symptoms of paranoia. A gainfully employed young African male adult reported to be roaming around town moving from one bank to another was arrested. The patient was referred to the psychiatric unit of a hospital and diagnosed with schizophrenia. Key interventions offered included rapid tranquilization, electroconvulsive therapy, and psychotherapy. Medications administered to the patient while on admission included IV diazepam, IM haloperidol, IV Ketamine, IM flupentixol, olanzapine tablets, and trihexyphenidyl tablets. Issues raised by clinical pharmacists during the patient’s admission included need for alternative medication for rapid tranquilization, need for initial investigations and documentation of the patient’s vitals, initiation of antipsychotic therapy without initial monitoring and screening for substance abuse, inappropriate dose at initiation of antipsychotic medications, untreated indication, and incidence of missed doses. Interventions by the clinical pharmacists contributed to improvement in the patient’s symptoms prior to hospital discharge. The case proves that it is critical for clinical pharmacists to be involved in the multidisciplinary team during management of patients with psychosis.

24 April 2020 in Case Reports in Psychiatry
Verified
Journal Article
Open access
PDF file
GAGrace Owusu Aboagye
Grace Owusu Aboagye
DADaniel Ankrah
Daniel Ankrah
Extrapyramidal side effects of psychotropic medicines are usually experienced by patients in the first few weeks of initiating therapy. Patients stabilized on these medications who present with distressing complaints akin to akathisia may be triggered by other factors. This report presents two cases of drug-drug-induced akathisia. Case A is a patient with schizophrenia who was being managed with risperidone 2mg tablet daily for the past 3 years. She fell ill and reported to a nearby clinic where she was prescribed ciprofloxacin and artemether/lumefantrine tablets for the treatment of an infection and malaria. She presented 7 days later to her psychiatrist with complaints of restlessness, tremor, palpitations, insomnia, and resurgence of obsessive thoughts. Case B is a patient who was diagnosed with first-episode psychotic depression and admitted for 10 days. Her medications on admission were fluphenazine decanoate 25mg depot injection once, olanzapine 10mg tablet daily, and fluoxetine 20mg capsule daily. On discharge, ciprofloxacin 500mg tablet every 12 hours for 5 days and fluconazole 150mg capsule once were added to her medications for the treatment of a urinary tract infection. She reported back to the hospital a day after discharge with complaints of restlessness, seizures, tremor, abdominal discomfort, and weight gain. Both patients were diagnosed with akathisia using ICD-10 classification and the Barnes akathisia rating scale and managed with anticholinergics, benzodiazepines, and beta blockers. Other measures employed in managing the akathisia included reducing the dose of the antipsychotic and/or switching antipsychotics. Despite these management measures, the symptoms of akathisia persisted and only resolved after 4weeks. Upon the resolution of symptoms, Case A continued treatment on olanzapine 5mg tablet daily and fluoxetine 20mg capsule daily while Case B continued treatment on risperidone 2mg tablet daily and fluoxetine 20mg capsule daily. Using Naranjos adverse drug reaction causality assessment scale, Medscape drug interaction checker, and literature review, a possible and probable case of drug-drug-induced akathisia was made for Case A and Case B. This report is to create more awareness about psychotropic-antimicrobial-induced akathisia. The information underpins the need for health professionals to consider adverse drug-drug interactions as the probable cause of extrapyramidal side effects experienced by patients on antipsychotics.

31 January 2024
Verified
Preprint
Open access
GAGrace Owusu Aboagye
Grace Owusu Aboagye
JMJosephine Mensah
Josephine Mensah
DLDaisy Naa Lamley Lamptey
Daisy Naa Lamley Lamptey
DKDesmond Kwakye
Desmond Kwakye
BABerko Panyin Anto
Berko Panyin Anto
Background: Antipsychotics are the mainstay in management of several mental health disorders. Antipsychotic induced weight gain is a predominant side effects seen in most patients. Objective: This investigation evaluated the interventions employed in addressing olanzapine induced weight gain in patients with severe mental disorders receiving treatment in a tertiary psychiatric setting. Methods: A retrospective observational study was conducted at Korle Bu Teaching Hospital. Data was collected from medical records of patients initiated on Olanzapine and reviewed using World Health Organization and American Society of Health System Pharmacist guidelines on drug evaluation to assess compliance with National Institute of Health and Clinical Excellence and British Association of Psychopharmacology guidelines on management of antipsychotic induced weight gain. Descriptive statistics was used to analyse data. Results: A total of 188 patients participated in the study. Less than half of the participants (n=57, 30.3%) experienced significant weight gain from the use of olanzapine, and interventions were recommended for 10 (18%) participants. Non-pharmacological interventions and modification in pharmacotherapy were initiated in 4 (40%) patients who received interventions. Adjunctive therapy with metformin was initiated in 1 (10%) patient. Cognitive behavioural therapy was not offered to any patient on account of weight gain. Interventions were administered promptly in 5 (50%) patients. Conclusion: Inadequate management of antipsychotic induced weight gain was evident. A multidisciplinary approach must be employed to ensure optimized management of antipsychotic induced weight gain. Keywords: Antipsychotic, Weight gain, Olanzapine, Intervention, Mental disorder